You are here

FDA Accepts Resubmitted NDA for Selegiline Antidepressant Patch

Pittsburgh, Pennsylvania/Corona, California - August 21, 2003 – Mylan Laboratories Inc. (NYSE: MYL) and Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing Somerset Pharmaceutical, Inc.’s EMSAM™ selegiline transdermal therapy for which Somerset is seeking marketing clearance for the treatment of depression. Somerset is a joint venture between Mylan and Watson.

The amendment to the New Drug Application includes additional clinical data evaluating the safety and efficacy of EMSAM™ at 20mg, 30mg and 40mg doses as compared to placebo. In addition, results from a 1 year relapse study and supplemental safety studies were submitted. The FDA has provided an action date of February 1, 2004.

Source: Mylan Laboratories Inc. and Watson Pharmaceuticals, Inc.

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications
Nexus Has Increased Power, RF Capabilities